SCHEMBL1369246

SCHEMBL1369246

Clc1nc(C2CC2)nc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGG1 O15527 1/20 0.53
PDE5A O76074 2/20 0.49
PDE10A Q9Y233 3/20 0.47
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
GBA1 P04062 1/20 0.45
METAP1 P53582 1/20 0.44
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16404345 1.00 OGG1 (0.53) OGG1PDE5APDE10AMAOAMAOB
SCHEMBL31052845 1.00 OGG1 (0.53) OGG1PDE5APDE10AMAOAMAOB
SCHEMBL15820506 0.93 PDE5A (0.54) OGG1PDE5APDE10AMAOAMAOB
SCHEMBL13356962 0.91 PDE5A (0.60) OGG1PDE5AL3MBTL1POLBKMT2A
SCHEMBL4836360 0.91 PDE5A (0.60) OGG1PDE5AL3MBTL1POLBKMT2A
SCHEMBL6337326 0.86 HTR3A (0.43) OGG1PDE5ATSHRMAPK1GBA1
SCHEMBL31391596 0.78 OGG1 (0.53) OGG1PDE5AMAOATSHRMAPK1
SCHEMBL30918000 0.78 DCPS (0.55) OGG1PDE5AMAOATSHRMAPK1
SCHEMBL4176703 0.78 DCPS (0.55) OGG1PDE5AMAOATSHRMAPK1
SCHEMBL12201249 0.77 MAOB (0.41) MAOAMAOBMETAP1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530652-B2 Pyrrolopyrazoles, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2013-09-10 US disclosed
US-20120264751-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. 2012-10-18 US disclosed
US-8067591-B2 Pyrrolopyrazole, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
EP-1838718-B1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PFIZER (US) 2011-06-15 EP disclosed
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS ZHANG JUNHU 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264751-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PAK4, PAK5, PAK3 OGG1 4687/4885PDE5A 651/4885PDE10A 703/4885
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS PAK4, PAK5, PAK3 OGG1 4822/4885PDE5A 733/4885PDE10A 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.